The 2025 ASCO Annual Meeting will be held from May 30 to June 3 in Chicago, USA. ASCO (American Society of Clinical Oncology) is the world’s largest and most authoritative clinical oncology meeting, bringing together many of the world’s leading oncology experts, and ASCO is an annual research event that publishes clinical oncology results from around the world.

Taivex Therapeutics will present the T-1201 Clinical Phase I Trial in Progress abstract in poster session at the meeting, and the majority of abstracts will be released on the official website of ASCO on May 23, 2025 (local time).

The abstract information is as follows:

Title: “Phase I multicenter, open-label, dose escalation study of T-1201, a small molecule drug conjugate, to assess safety, pharmacokinetics, and antitumor activity in advanced solid tumors”

Abstract Number: TPS3162

Date and time: 2025/6/2 13:30-16:30 (Local time)